uniQure (QURE) AI Stock Analysis

• Market Cap: $675.96M
• Dividend Yield: N/A
• Average Volume (3M): 916.81K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.91
• Revenue Growth: 71.17%
• EPS Growth: 23.89%
• Country: US
• Employees: 480
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -4.92
• Shares Outstanding: 54,076,880
• 10 Day Avg. Volume: 1,044,899
• 30 Day Avg. Volume: 916,814
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 24.93
• Price to Cash Flow (P/CF): -3.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $33.71
• Price Target Upside: 144.63% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

uniQure's stock score is primarily weighed down by financial instability, with persistent losses and liquidity issues posing significant risks. However, the technical analysis shows some support in longer-term trends, and the recent positive corporate event regarding FDA progress for AMT-130 offers a potential catalyst for future growth. Valuation remains weak, reflecting the company's current financial difficulties.

Positive Factors

Market Potential

Huntington's is an area with high unmet need, as there are no disease-modifying therapies currently approved.

Regulatory Approval

The company aligns with the FDA on the components of an accelerated approval BLA for AMT-130 in HD, which could significantly reduce development time.

Negative Factors

Financial Performance

Net loss per share was significantly higher than consensus expectations.

uniQure Business Overview & Revenue Model

Company Description

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

How the Company Makes Money

uniQure generates revenue primarily through strategic collaborations, licensing agreements, and the development and commercialization of its proprietary gene therapy products. Key revenue streams include milestone payments and royalties from partnerships with larger pharmaceutical companies. These collaborations often involve the co-development and commercialization of gene therapies, providing uniQure with financial support and access to broader markets. Additionally, uniQure seeks to commercialize its own therapies, aiming to receive direct sales revenue upon product approval and market launch. The company's earnings are significantly influenced by its ability to successfully advance its product pipeline through clinical trials and regulatory approvals, as well as its capacity to secure and maintain strategic alliances.

uniQure Financial Statement Overview

Summary

uniQure faces considerable financial challenges across all verticals. The income statement shows declining revenue and persistent losses, the balance sheet indicates financial distress with negative equity, and cash flow statements highlight liquidity issues. The company's financial health appears precarious, with significant risks that need addressing.

Income Statement

The income statement reveals substantial volatility in revenue with significant fluctuations over the years. The company experienced a revenue peak in 2021 but faced a sharp decline afterward. Net profit margins have been consistently negative, with a significant net loss in recent periods. The gross profit margin has seen a decline, indicating increased operational challenges. Overall, the company is struggling with profitability and stability.

Balance Sheet

The balance sheet shows high financial risk with negative stockholders' equity in the latest period, indicating insolvency concerns. The debt-to-equity ratio cannot be calculated due to negative equity, but the high total liabilities relative to assets emphasize leverage risk. The equity ratio is negative, reflecting financial instability. Overall, the balance sheet suggests significant financial distress.

Cash Flow

Cash flow analysis indicates negative free cash flow, with recent deterioration in operating cash flow. Despite a large influx from investing activities, it is not sufficient to cover the negative free cash flow, highlighting potential liquidity issues. The ratios related to net income cannot be calculated due to persistent net losses. Overall, cash flow management appears weak with ongoing challenges in generating positive cash flow.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
27.12M	15.84M	106.48M	524.00M	37.51M
	Gross Profit
25.85M	2.21M	103.14M	499.03M	-84.89M
	EBIT
-184.29M	-282.87M	-143.16M	310.62M	-125.43M
	EBITDA
-160.75M	-253.10M	-108.02M	319.00M	-126.97M
	Net Income Common Stockholders
-239.56M	-308.48M	-126.79M	329.59M	-125.02M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
367.52M	617.89M	352.84M	556.26M	244.93M
	Total Assets
556.54M	831.69M	704.96M	809.18M	340.39M
	Total Debt
66.06M	138.41M	142.89M	135.72M	71.54M
	Net Debt
-92.87M	-102.95M	-85.12M	-420.53M	-173.39M
	Total Liabilities
563.29M	624.02M	228.96M	213.40M	96.49M
	Stockholders Equity
-6.75M	207.67M	476.01M	595.78M	243.91M
Cash Flow		Free Cash Flow
-186.10M	-153.08M	-162.75M	270.52M	-144.31M
	Operating Cash Flow
-182.73M	-145.93M	-145.06M	287.96M	-134.83M
	Investing Cash Flow
162.97M	-205.69M	-182.73M	-67.39M	-9.48M
	Financing Cash Flow
-59.49M	362.72M	1.45M	94.86M	7.44M

uniQure Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13.78
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QURE, the sentiment is Positive. The current price of 13.78 is above the 20-day moving average (MA) of 12.48, below the 50-day MA of 14.27, and above the 200-day MA of 8.83, indicating a neutral trend. The MACD of -0.34 indicates Negative momentum. The RSI at 54.78 is Neutral, neither overbought nor oversold. The STOCH value of 85.78 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QURE.

uniQure Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BMRN	78 Outperform	$13.46B	32.10	8.05%	―	17.35%	151.40%
SRPT	69 Neutral	$9.77B	41.86	19.71%	―	52.97%	―
Sector *	49 Neutral	$6.84B	0.05	-53.14%	2.48%	24.49%	-3.26%
CRSP	46 Neutral	$3.63B	―	-19.20%	―	-89.95%	-123.71%
QURE	45 Neutral	$675.96M	―	-238.46%	―	71.17%	23.89%
BLUE	42 Neutral	$38.57M	―	-270.20%	―	144.50%	-141.91%
ADVM	42 Neutral	$100.68M	―	-76.26%	―	-72.22%	51.95%

uniQure Corporate Events

uniQure Secures FDA Agreement for AMT-130 Approval

uniQure has reached an agreement with the FDA on critical elements for the Accelerated Approval pathway for AMT-130, a promising gene therapy for Huntington’s disease. The FDA’s acceptance of data from Phase I/II studies, along with the use of cUHDRS as a clinical endpoint, marks a significant milestone towards delivering this potential treatment. The company plans to engage further with the FDA in 2025, aiming to expedite the availability of AMT-130, which has shown promising results in slowing disease progression.